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Background: Erythrocyte invasion by Plasmodium falciparum is a complex process that involves two families;
Erythrocyte Binding-Like (EBL) and the Reticulocyte Binding-Like (PfRh) proteins. Antibodies that inhibit merozoite
attachment and invasion are believed to be important in mediating naturally acquired immunity and immunity
generated by parasite blood stage vaccine candidates. The hypotheses tested in this study were 1) that antibody
responses against specific P. falciparum invasion ligands (EBL and PfRh) differ between symptomatic and
asymptomatic individuals living in the low-transmission region of the Peruvian Amazon and 2), such antibody
responses might have an association, either direct or indirect, with clinical immunity observed in asymptomatically
parasitaemic individuals.
Methods: ELISA was used to assess antibody responses (IgG, IgG1 and IgG3) against recombinant P. falciparum
invasion ligands of the EBL (EBA-175, EBA-181, EBA-140) and PfRh families (PfRh1, PfRh2a, PfRh2b, PfRh4 and PfRh5)
in 45 individuals infected with P. falciparum from Peruvian Amazon. Individuals were classified as having
symptomatic malaria (N=37) or asymptomatic infection (N=8).
Results: Antibody responses against both EBL and PfRh family proteins were significantly higher in asymptomatic
compared to symptomatic individuals, demonstrating an association with clinical immunity. Significant differences
in the total IgG responses were observed with EBA-175, EBA-181, PfRh2b, and MSP119 (as a control). IgG1 responses
against EBA-181, PfRh2a and PfRh2b were significantly higher in the asymptomatic individuals. Total IgG antibody
responses against PfRh1, PfRh2a, PfRh2b, PfRh5, EBA-175, EBA-181 and MSP119 proteins were negatively correlated
with level of parasitaemia. IgG1 responses against EBA-181, PfRh2a and PfRh2b and IgG3 response for PfRh2a were
also negatively correlated with parasitaemia.
Conclusions: These data suggest that falciparum malaria patients who develop clinical immunity (asymptomatic
parasitaemia) in a low transmission setting such as the Peruvian Amazon have antibody responses to defined
P. falciparum invasion ligand proteins higher than those found in symptomatic (non-immune) patients. While
these findings will have to be confirmed by larger studies, these results are consistent with a potential role for
one or more of these invasion ligands as a component of an anti-P. falciparum vaccine in low-transmission
malaria-endemic regions.
Keywords: Antibodies, Invasion, Plasmodium falciparum, Malaria, Peru* Correspondence: jvinetz@AD.UCSD.EDU; slustigman@nybloodcenter.org
†Equal contributors
1Malaria Laboratory, Instituto de Medicina Tropical “Alexander von
Humboldt”, Universidad Peruana Cayetano Heredia, Lima, Peru
3Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias y
Filosofia, Universidad Peruana Cayetano Heredia, Lima, Peru
Full list of author information is available at the end of the article
© 2012 Villasis et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Villasis et al. Malaria Journal 2012, 11:361 Page 2 of 9
http://www.malariajournal.com/content/11/1/361Background
Erythrocyte invasion by Plasmodium falciparum is a
complex process including attachment, reorientation,
penetration, and formation of a parasitophorous vacuole.
Several merozoite proteins that have a role during the
initial steps of attachment and invasion have been ex-
tensively studied, including members of the Merozoite
Surface Protein family (MSP), AMA-1, Erythrocyte
Binding-Like proteins (EBL: EBA-175, EBA-181, EBA-140
and EBL-1), and the Reticulocyte Binding-Like or Reticu-
locyte Homologue proteins (RBL or PfRh: PfRh1, PfRh2a,
PfRh2b, PfRh4 and PfRh5) [1]. Many of the invasion
ligands are currently being evaluated or developed as
candidate vaccine antigens for inclusion in an anti-
erythrocytic-stage malaria vaccine [2]. Antibodies that
inhibit merozoite attachment and invasion, and thus sub-
sequent development and propagation within the red
blood cells (RBC), are believed to be important in medi-
ating naturally acquired immunity as well as immunity
generated by parasite blood stage vaccine candidates [3].
Moreover, the cytophilic IgG1 and IgG3 antibody isotype
subclasses have been reported to be associated with pro-
tective responses generated against invasion ligands [4-6],
by enabling the activation of complement and antibody-
dependent phagocytosis and consequently parasite clear-
ance [7]. However, it remains unclear which merozoite
invasion ligand antigens might be the most important
targets of naturally acquired clinical immunity, and
whether the importance of such antigens are of regional
specificity or globally relevance [2].
Malaria in the Amazonian region is hypoendemic and
characterized by a low transmission [8]. The malaria
infections are most commonly caused by Plasmodium
vivax, but P. falciparum is still responsible for the major
cases of severe malaria, and these infections continue to
persist even though control measures are in place [9]. Pre-
vious studies in this region have demonstrated that clinical
immunity to malaria is manifested by the presence of indi-
viduals with asymptomatic parasitaemia, which is not in-
frequent [8,10]. Importantly, asymptomatic parasitaemia
has major implications for public health, particularly in
maintaining transmission including the introduction or
reintroduction of parasites in endemic regions that stopped
having malaria. Understanding the immune mechanisms
by which infected humans control parasitaemia in the
absence of symptoms has important implications for
developing anti-malarial vaccine strategies [10]. In indi-
viduals living in areas of intense P. falciparum trans-
mission clinical immunity to symptomatic malaria is
thought to be acquired only after repeated exposure [2].
In contrast, studies have demonstrated in Indonesia
and in Amazonia that acquisition of clinical immunity
can be rapid (within two years), especially in adults, and
may require few infections [9-15]. This observationclearly indicates that non-sterilizing but effective clinical
anti-malarial immunity develops in low transmission
regions [9].
Given the epidemiological observations indicating
clinical immunity against P. falciparum, this study aimed
to test the hypothesis that antibody responses against
P. falciparum invasion ligands belonging to both EBL
and PfRh protein families might differ between symp-
tomatic (Sym) and asymptomatic (Asy) individuals living
in the low-transmission region of the Peruvian Amazon,
and hence potentially contributing to explaining mechan-
isms of clinical immunity observed in the Asy individuals.
Recombinant P. falciparum proteins corresponding to
the known EBL and PfRh invasion ligands were used to
determine the total IgG and IgG isotype-specific antibody
responses in both study groups.Methods
Study population
This study was approved by the Universidad Peruana
Cayetano Heredia Institutional Review Board (Comite de
Etica) in Lima, Peru, and by the New York Blood Center’s
IRB (protocol #415). Informed consent was obtained
from each adult individual or from the parents or guar-
dians of children less than 18 years of age. The cross-
sectional study took place in the Peruvian Amazon region
of Loreto in 2008–2010.
A total of 45 plasma samples from individuals infected
with P. falciparum were collected over the period of
2008–2010 from 14 different communities in Loreto. The
individuals were classified into two groups: 37 individuals
with symptomatic malaria (16 females and 21 males;
median age = 29; range 9–63 years) and eight individuals
with asymptomatic infection (one female and seven males;
median age = 26; range 12–43 years). Asymptomatic
individuals were identified by active case detection after
carrying out a malaria diagnostic survey in communities
that reported a malaria outbreak. Passive case detection
was used to enroll symptomatic individuals who attended
the local Health Care Center for diagnosis and treatment
and were diagnosed with P. falciparum infection by light
microscopy. The microscopic diagnosis in all individuals
enrolled was confirmed as P. falciparum single infection
by real time PCR [16]. Individuals were classified as Asy
if they did not have any signs or symptoms related to
malaria [eg. fever (temperature >37°C), chills, sweating,
headache or any other kind of symptoms that the subject
interpreted as indicating malaria but were positive by
blood smear for P. falciparum]. Individuals were excluded
if they used anti-malarial medication over the two weeks
before enrollment and sample collection. No follow up
was done. Blood samples were collected before all indivi-
duals were treated for malaria with mefloquine/artesunate
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Proteins used in the ELISA assays
The following recombinant EBL and PfRh proteins cor-
responding to the P. falciparum 3D7 laboratory strain
were used for ELISA. The C-terminal region of EBA-181
(aa 1235–1345), PfRh1 (aa 1318–1574), PfRh2a (aa 2813–
2933), PfRh2b (aa 2735–3133) and PfRh5 (aa 31–174)
were expressed in Escherichia coli BL21. PfRh2b and
PfRh5 were expressed as fusion proteins with glutathione
S-transferase (GST) using the pGEX 4T-3 expression
vector (Amersham Biotech, NJ). The E. coli expressed
PfRh4 (aa 1160–1370) protein was a kind gift from
Deepak Gaur (ICGEB; New Delhi, India) and Louis
Miller (NIH, USA) [17]. Fragments corresponding to
the region II of EBA-175 (aa 145–760) and EBA-140
(aa 141–756) were expressed in Pichia pastoris and were
a kind gift from David Narum and Louis Miller (NIH,
USA) [5]. The recombinant protein corresponding to the
19-kDa processed fragment of MSP-1 (MSP119; MRA-55,
MR4, ATCC Manassas Virginia) was also used as a
control [18].
IgG responses against P. falciparum invasion ligands as
determined by ELISA
Peruvian plasma samples were analyzed for total IgG,
IgG1 and IgG3 reactivity to the recombinant EBL and
PfRh ligands by ELISA as previously described [19].
Plasma samples were pre-incubated with E. coli extract
prior to dilution and incubation with the bound antigen
to remove antibodies to potential E. coli contaminants in
the recombinant protein preparations. Briefly, 96-well
ELISA plates (Costar, Corning Life Sciences, Corning,
NY) were coated with 1 μg/mL of the recombinant pro-
tein (0.5 μg/mL for PfRh4) in 0.05 M carbonate buffer,
pH 9.6 overnight at 4°C. The next day, plates were
washed 6 times with phosphate-buffered saline (PBS) con-
taining 0.05% Tween 20 (PBST) and blocked for 1.5-2 h
with blocking buffer (3% BSA in PBST) at 37°C. Plates
were washed with PBST and test and control plasma
samples (1:200) diluted in blocking buffer were added
into each well in duplicate for 2 h at 37°C. The plates
were then washed 6 times with PBST and the bound
IgG antibodies were detected after 1 h of incubation at
37°C using HRP-conjugated goat anti-human (1:1,000)
IgG (H+L; Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD). IgG1 and IgG3 antibodies were
detected after incubation for 1 hr at 37°C with mouse
monoclonal antibodies against human IgG1 or IgG3
(Hybridoma Reagent Laboratory, Baltimore, MD) diluted
1:1,000 in blocking buffer, followed by HRP-conjugated
anti-mouse (1:1250). After 6X washing with PBST,
bound antibodies were detected by adding the SureBluetetramethyl benzidine (TMB) substrate (Kirkegaard and
Perry Laboratories, Inc., Gaithersburg, MD). The reac-
tion was stopped by the addition of 2N H2SO4, and the
Optical Density (OD) at 450 nm was measured using a
SpectraMax 190 ELISA Reader (Molecular Devices,
Sunnyvale, CA). For the GST-fusion PfRh2b and PfRh5
proteins, each plasma sample was also tested against re-
combinant GST as a negative control and the corre-
sponding absorbance was deducted from all test values
for the fusion proteins. The negative control human
serum was composed of a pool of sera from five healthy
adult volunteers living in USA who had never been
exposed to malaria. Positive responders were defined as
those that gave an OD value greater than the mean plus
three standard deviations (SD) of the reactivity observed
with negative control serum (cut-off value).
Statistical analysis
Fisher’s exact test (2x2 contingency tables) was used to
compare differences in the seroprevalence between
groups. The Mann–Whitney test was used to compare
medians between different groups. Correlations be-
tween antibody response (as indicated by OD) and
parasitaemia or age were examined using Spearman’s
test. A p value < 0.05 was considered statistically signifi-
cant. Statistical analyses were performed using GraphPad
Prism software (version 5.01; GraphPad Software Inc., San
Diego, CA, USA).
Results
Differential antibody responses in asymptomatic vs
symptomatic individuals
Two groups of individuals were studied; individuals with
symptomatic malaria (Sym, N =37) and individuals with
asymptomatic infection (Asy, N=8). There were no signifi-
cant differences in the sex distribution or median of age
between the groups. Parasitaemia was lower in the Asy
(median 519 parasites/μL; range 24–2874 parasites/μL)
than in the Sym individuals (median 7056 parasites/μL;
range 239–61,185 parasites/μL) (p < 0.0001).
Samples were tested against a comprehensive panel of
known EBL and PfRh ligands except EBL-1; a majority
of the Peruvian P. falciparum field isolates do not express
EBL-1 as the gene in these parasites contained a five-
thymidine insertion that results in premature translational
termination and lack of protein expression [Lopez-Perez
M et al., manuscript in preparation]. Antibodies against
MSP119, an immunogenic merozoite protein targeted as
a vaccine protein, were measured for comparison. The
percentage of responders against this antigen was 100%
in Asy vs. 54% in the Sym (Table 1). Based on the total
IgG responses against the EBL and PfRh invasion ligands,
the percentage of responders in the Asy vs. the Sym group
varied for some. In general, a higher seroprevalence was
Table 1 Percentages of individuals within the Asymptomatic (Asy) and Symptomatic (Sym) malaria groups responding
(total IgG) to EBL and PfRh ligands
Ligand PfRh1 PfRh2a PfRh2b PfRh4 PfRh5 EBA- 175 EBA- 140 EBA-181 MSP-119
Asy 100% 75% 75% 71% 25% 100% 25% 88% 100%
Seropositive (8/8) (6/8) (6/8) (5/7) (2/8) (8/8) (2/8) (7/8) (8/8)
Sym 86.5% 75.7% 21.6% 47% 8.1% 32. 4% 5.4% 21.6% 54%
Seropositive (32/37) (28/37) (8/37) (17/36) (3/37) (12/37) (2/37) (8/37) (20/37)
Cut-off value 0.13 0.12 0.1 0.1 0.16 0.16 0.41 0.12 0.16
p (Fisher Test) ns ns 0.007 ns ns 0.0006 ns 0.0009 0.0171
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PfRh1, PfRh2b and PfRh4 than in Sym individuals. The
percentage of responders against PfRh2a was similar
(75%). Notably, there were fewer responders in both
groups against EBA-140 (25% and 5.4%) and PfRh5 (25%
and 8.1%) (Table 1). When the seroprevalence between
both groups for each invasion ligand was compared, it
appeared that the percentage of responders in the Asy
individuals was significantly higher than in the Sym
group only against EBA-175 (p = 0.0006), EBA-181
(p = 0.0009) and PfRh2b (p = 0.007) as well as against the
control merozoite protein, MSP119 (p = 0.0171). Signifi-
cantly, a higher total IgG response, as indicated by the OD
value, was observed in Asy than Sym individuals for EBA-
175 (median OD 1.08 vs. 0.15; p = 0.0001), EBA-181 (me-
dian OD 0.50 vs. 0.11; p = 0.0004), PfRh1 (median OD
0.23 vs. 0.16; p = 0.0006) and PfRh2b (median OD 0.36
vs. 0.01; p = 0.0022) as well as for MSP119 (median OD
0.90 vs. 0.17; p = 0.0005) (Figure 1).
Total IgG and isotype responses against some of the
invasion ligands are also associated with reduced
parasitaemia
As Asy individuals had significantly lower parasitaemia
than Sym, ELISA was used to determine whether IgGFigure 1 Total IgG responses to EBL and PfRh ligands in Symptomati
total IgG responses (as indicated by optical density, OD) in asymptomatic (
indicated by horizontal bars. Abbreviations: Asy, open symbols; Sym, closelevels, as indicated by optical density, were also negatively
associated with parasitaemia (parasites/μL). A significant
negative correlation was observed between the total IgG
levels and parasitaemia for the following invasion ligands:
PfRh1 (p < 0.0001, rs = −0.565), PfRh2a (p = 0.007,
rs = −0.499), PfRh2b (p = 0.0004, rs = −0.515), PfRh5
(p = 0.016, rs = −0.364), EBA-175 (p = 0.0004, rs = −0.516),
EBA-181 (p = 0.0001, rs = −0.546) as well as for
MSP119 (p < 0.00001, rs = −0.619). The total IgG responses
against EBA-140 and PfRh4 ligands were not associated
with levels of parasitaemia (Figure 2).
IgG1 and IgG3 isotype-specific antibody responses to the
EBL and PfRh ligands
IgG1 and IgG3 are the predominant isotypes pro-
duced in response to merozoite invasion ligands [4-6],
and these isotypes are associated with being cytophilic
and mechanistically killing parasitized RBCs by antibody-
dependent cell-mediated inhibition (ADCI) [7]. Thus,
to gain additional insights in the differential anti-
body response generated in the Asy and Sym indivi-
duals under natural infection conditions, we measured
IgG1 and IgG3 responses for PfRh2a, PfRh2b, PfRh5
and EBA-181, for which a higher total IgG response
was observed to be negatively correlated with lowerc and Asymptomatic Peruvian individuals. Comparison between the
Asy) and symptomatic (Sym) Peruvian individuals. Median values are
symbols; ns, not significant; ** p < 0.01; *** p < 0.001.
Figure 2 Total IgG response to EBL and PfRh ligands in Symptomatic and Asymptomatic malaria infected Peruvian individuals in
relationship with their parasitaemia. The parasitaemia was determined by light microscopy and expressed as parasites/μL. Spearman
correlation coefficient, abbreviated rs, and p value are shown.
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was observed in the Asy than the Sym group against
EBA-181 (88% vs. 24%; p = 0.002), PfRh2a (88% vs. 38%;
p = 0.017) and PfRh2b (88% vs. 24%; p = 0.003). The
prevalence of IgG3 responders was higher in Asy than
Sym for PfRh2a (75% vs. 30%; p = 0.039) and PfRh5
(38% vs. 3%; p = 0.014).
Differences in IgG1 and IgG3 responses between the Asy
\and Sym individuals were also observed (Figure 3).
gG1 responses for EBA-181 (median OD 0.46 vs.
0.09; p = 0.0006) and PfRh2b (median OD 0.36 vs.
0.07; p = 0.0017) were significantly higher in the Asy
than the Sym group. Notably, both IgG1 and IgG3 were
dominant in the Asy group for PfRh2a (median IgG1 OD
0.70 vs. 0.19; p = 0.0018 and median IgG3 OD 0.34 vs. 0.2;
p = 0.0206).
Notably, IgG1 and IgG3 levels were also significantly
associated with lower parasitaemia (Figure 4). A negative
correlation was observed between parasitaemia and the
IgG1 levels for EBA-181 (p = 0.0007; rs = −0.495),PfRh2a (p = 0.0178; rs = −0.360) and PfRh2b (p = 0.015;
rs= −0.368), and the IgG3 levels for PfRh2a (p = 0.0028;
rs = −0.445).
Discussion
This study is the first to comprehensively analyse the pro-
file of naturally acquired antibodies against the two major
families of P. falciparum merozoite ligands in asymp-
tomatic vs symptomatic populations living in a malaria
hypoendemic area. Sera from P. falciparum-infected
individuals from the Peruvian Amazon were tested against
all PfRh and EBL family members known to be involved in
P. falciparum invasion. This study’s main finding is that
antibody responses against the EBL and PfRh proteins
were significantly higher in asymptomatic than symptom-
atic parasitaemic individuals, suggesting a potential associ-
ation with the development of clinical immunity. Whether
these anti-invasion ligand antibodies directly mediate
protective immunity or are simply statistically associated
with clinical immunity is beyond the scope of this pilot
Figure 3 Comparison of IgG1 and IgG3 isotypes-specific antibody response to EBA-181 and PfRh ligands in asymptomatic and
symptomatic Peruvian individuals. Comparison between the IgG1 and IgG3 responses (as indicated by optical density, OD) against some of
the invasion ligands in asymptomatic (Asy) and symptomatic (Sym) Peruvian individuals. Median values are indicated by horizontal bars.
Abbreviations: Asy, open symbols; Sym, close symbols; ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
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were observed against EBA-175, EBA-181, PfRh2b and
MSP119. IgG1 responses against EBA-181, PfRh2a and
PfRh2b were also significantly higher in the asymptom-
atic individuals. Furthermore, elevated total IgG antibody
responses against PfRh1, PfRh2a, PfRh2b, PfRh5, EBA-
175, EBA-181 and MSP119 proteins were positively asso-
ciated with decreased parasitaemia. IgG1 response against
EBA-181, PfRh2a and PfRh2b and IgG3 response for
PfRh2a were also negatively correlated with parasitaemia.
Thus, these results suggest that total and IgG subclass-
specific responses to distinct merozoite antigens are sig-
nificantly associated with protection from high-density
parasitaemia and symptomatic malaria.
IgG responses to some but not all EBL antigens has
been associated with protection against symptomatic
P. falciparum in some malaria endemic areas (reviewed
in [1]). Naturally acquired antibodies to region II of
EBA-175 have been found to increase with age in a nat-
urally exposed population in Kenya and such antibodies
were capable of inhibiting binding of EBA-175RII to
erythrocytes as a correlate of clinical immunity in this
population affected by holoendemic malaria [20]. None-
theless, significant associations between anti-EBA-175
antibody levels and protection from high-density parasit-
aemia and clinical disease has been inconsistent among
studies [20-23] although experimental studies using
sera from rabbits vaccinated with region II of EBA-175
were able to block invasion by > 50% of P. falciparum
laboratory strains from diverse geographic origin [24,25].
Studies that measure responses to the other EBL antigens
in endemic areas outside of Africa are scarcer [5,9,19].
A comparative study by Ford et al., showed that the
antibody responses against MSP119 and EBLs (EBA-175,
EBA-140, EBA-181) in individuals living in a hypoendemicmalaria region of Brazil were much lower thanin indivi-
duals living in a hyperendemic area of Cameroon
[19].
Immune responses against PfRh invasion ligands have
been less studied [4,26,27]. Association between anti-
body responses against PfRh ligands and outcome of a
clinical disease has been reported only for PfRh2a and
PfRh2b [4]. Antibody responses against PfRh4, PfRh5
and the common region of PfRh2 were reported for sub-
jects in Kenya without taking into consideration the
clinical or parasitological status of the studied individuals
[27], and responses against PfRh2b was also evaluated in
subjects from Senegal and Tanzania [26]. In children
from Papua New Guinea, high levels of total IgG as
well as IgG1 and IgG3 antibody responses against the
PfRh2a and PfRh2b antigens were found to be strongly
associated with protection from symptomatic malaria
and high-density parasitaemia. Notably, these antibody
responses were similar to or greater than the ones gener-
ated against the leading vaccines candidates MSP119,
MSP-2 and AMA-1 [4], but, it must be noted, that differ-
ent regions of the EBAs and the PfRH proteins were
studied so it may be difficult to make direct comparisons
[4]. Antibody responses against PfPh5 have been found
at much lower rates in naturally infected individuals but
laboratory studies of anti-PfRh5 antibodies induced by
vaccination with recombinant protein appeared to induce
strain-transcending growth inhibitory antibodies [25,27].
The focus on PfRh invasion ligands as potential vaccine
antigens was augmented by the recent promising inva-
sion inhibitory results obtained using antibodies gener-
ated against the combination of EBL and PfRh proteins;
EBA-175, PfRh2 and PfRh4 [28], and EBA-175 and PfRh5
[25]. The ability of antibodies against the full length
PfRh5 (RH5FL) protein to inhibit the growth of all strains
Figure 4 Association between parasitaemia and the IgG1 and IgG3 antibody response to EBA-181, PfRh2a, PfRh2b and PfRh5
P. falciparum ligands. The parasitaemia was determined by light microscopy and expressed as parasites/μL. Spearman correlation coefficient,
abbreviated rs, and p value are shown. Triangles, IgG1 and Circles, IgG3.
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induced by other vaccine candidates, such as AMA-1
and MSP-1, increased the appeal of using PfRh5 as an
anti-blood-stage malaria vaccine [27].
Three studies have previously examined the presence
of antibodies against PfRh ligands [4,26,27], but not
against PfRh1 in an endemic population. Notably, total
IgG response to PfRh1 in the Peruvian population was
similar in Sym and Asy individuals based on seropreva-
lence, but the magnitude of the response was signifi-
cantly higher in the Asy group and inversely associated
with levels of parasitaemia. A high seroprevalence for
PfRh2a (75%) regardless of the clinical status (Asy andSym) was observed in the Peruvian individuals similar to
what was reported in children from Papua New Guinea
(94%) [4]. However, in Peruvian subjects, significant dif-
ferences were observed in the prevalence of IgG1 and
IgG3 responders in the Asy group (IgG1 88% vs. 38%
and IgG3 75% vs. 30%). In contrast, the response against
PfRh2b in the Peruvians (31%) was higher than that
reported in individuals with malaria in Senegal (8.9%)
and Tanzania (5.6%) and lower than those observed in
Papua New Guinea (85%) [4,26]. However, higher total
IgG and IgG1 responses against the PfRh2b ligand were
associated with low parasitaemia, similar to observed in
Papua New Guinea [4]. Seroprevalence for PfRh4 in the
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adults from Kenya (50% vs. 70%) [27], and presently it
appears that these antigen specific responses are not
associated with protection against clinical malaria. In
this study only IgG1 and IgG3 subtypes were measured
and analysed because these subtypes are associated with
Fc binding and are potentially associated with functional
antibody-dependent cellular cytotoxicity [29,30]. None-
theless, whether such anti-invasion ligand antibodies
might function through ADCI, steric hindering or by
another mechanism remains to be determined. Although
PfRh5 was suggested to be essential for erythrocyte in-
vasion [31,32] and the target for vaccine-induced anti-
bodies [27], only few individuals from Peru had antibodies
against PfRh5 (11%), which is comparable to what was
reported in Kenya (16%) [27]. The reason for the lack of
anti-PfRh5 antibody in naturally exposed individuals is
still unclear. The mechanism by which this essential inva-
sion ligand escapes immune recognition thus requires
further investigation.
Conclusions
Although the contribution of the anti-invasion EBL
and/or PfRh ligand antibody responses to protective
immunity needs to be confirmed in future studies by
functional assays such as growth inhibition assays, the
present study strongly suggests that the Peruvian popula-
tion present in a low transmission setting has a capacity
to develop clinical immunity that is likely associated with
antibody responses to defined P. falciparum invasion
ligands. These results are consistent with a potential role
for one or more of these invasion ligands as a component
of an anti-P. falciparum vaccine in the low-transmission
areas of the Amazon region, but may argue against a
one-size fits all strain-transcending blood stage malaria
vaccine.
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